Athersys Announces Fast Track Designation From FDA for MultiStem® Program for Acute Respiratory Distress Syndrome

NEXT STORY
Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update
PREV STORY
Uveitis Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments: Pharma Proff
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Athersys Announces Fast Track Designation From FDA for MultiStem® Program for Acute Respiratory Distress Syndrome

NEXT STORY
Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update
PREV STORY
Uveitis Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments: Pharma Proff
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer

author_avatar
NASDAQ Market News

MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology

author_avatar
NASDAQ Market News

Global Fluid Management Systems Market (2020 to 2025) – Single-Use Disposable Devices and Accessories Presents Opportunities

author_avatar
NASDAQ Market News